FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Sunovion Pharmaceuticals sNDA for Antiepileptic Drug

Sunovion Pharmaceuticals files a supplemental NDA to expand the indication for its antiepileptic drug Aptiom (eslicarbazepine acetate) to include use ...

Human Drugs

Sharfstein, Others Aim to Kickstart FDA Transparency

Researchers from a number of institutions, led by former FDA principal deputy commissioner Josh Sharfstein, develop a new Blueprint for Transparency a...

Human Drugs

FDA Approves Novartis Breast Cancer Therapy

FDA approves Novartiss Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women wit...

Medical Devices

FDA Clears Medtronic Reveal LINQ Cardiac Monitor

FDA clears a Medtronic 510(k) for its Reveal LINQ Insertable Cardiac Monitor with TruRhythm Detection, an advanced cardiac monitor offering designed t...

FDA General

We Endorse Scott Gottlieb for FDA Commissioner

For the first time in our 35-year history of FDA news coverage, we endorse a candidate for FDA commissioner: Trumps choice of former deputy commission...

FDA General

FDA Mulls New Patient Affairs Office

FDA seeks comments on its ongoing efforts to enhance mechanisms for patient engagement at the agency, including establishing a new Office of Patient A...

Human Drugs

von Eschenbach on Reforming Drug Development

Former FDA commissioner Andrew von Eschenbach co-authors an opinion piece on increased resources needed to advance activities such as the Critical Pat...

Human Drugs

Guidance on Hypertension Drug Labeling

FDA posts a guidance on Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims that is intended to help applicants in developing lab...

Federal Register

FDA/Health Canada Public Meeting on ICH Activities

Federal Register Notice: FDA announces a regional public meeting entitled U.S. Food and Drug Administration and Health Canada Joint Regional Consultat...

FDA General

Since Our Last Issue ...

Industry news you may have missed since our last issue.